| Original language | English (US) |
|---|---|
| Pages (from-to) | 421-426 |
| Number of pages | 6 |
| Journal | Journal of general internal medicine |
| Volume | 24 |
| Issue number | 3 |
| DOIs |
|
| State | Published - Mar 2009 |
Keywords
- Constipation
- Dementia screening
- Gait speed
- Geriatrics
- Hip arthritis
- Osteoporosis
ASJC Scopus subject areas
- Internal Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of general internal medicine, Vol. 24, No. 3, 03.2009, p. 421-426.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Update in geriatric medicine
AU - Day, Hollis D.
AU - Eckstrom, Elizabeth
AU - Sullivan, Gail M.
N1 - Funding Information: This study was sponsored by: Merck Research Laboratories, Pittsburgh Claude D. Pepper Center, National Institute on Aging, and Hartford Foundation Pittsburgh Center of Excellence in Geriatric Medicine. Merck employees participated in the design of the original study and the analyses to identify criteria for meaningful change. Merck employees also reviewed the manuscript and provided feedback. Funding Information: Zoledronic acid is effective in reducing fractures in postmenopausal women, with an efficacy similar to that of oral bisphosphonates. It has not been compared head to head with oral bisphosphonates. Though this was a large population, it was probably not sufficient to sort out true risks; therefore, continued adverse event surveillance is necessary. Once-yearly zoledronic acid improves compliance over oral bisphospho-nates and is a reasonable choice for osteoporosis patients who do not tolerate or are non-compliant with oral bisphospho-nates. Of note, zoledronic acid costs approximately $1,100 for a once-yearly injection (not including infusion costs), comparing unfavorably with generic alendronate, and is not covered by many Medicare Part D plans. This study was sponsored by Novartis Pharma; many on the investigator team received support from Novartis. The study was jointly designed by members of the steering committee and the sponsor. The sponsor had responsibility for data collection and quality control. UCSF hosted the data and safety monitoring board. Analysis was performed by the sponsor, but independently Funding Information: The results from this study should prompt clinicians to refer patients with hip OA that is symptomatic, unresponsive to maximum tolerated doses of analgesia and other medical treatments, and interferes with quality of life/function to interventional radiologists for corticosteroid injection. This study was sponsored by: CHAR/Nycomed Development Award, MSI Foundation, University of Alberta Hospital Foundation, and Arthritis Society of Canada. Funding Information: This study was supported by the Institute for Medical Research at the Durham VA Medical Center, Paul B. Beeson K23 Career Development Award.
PY - 2009/3
Y1 - 2009/3
KW - Constipation
KW - Dementia screening
KW - Gait speed
KW - Geriatrics
KW - Hip arthritis
KW - Osteoporosis
UR - http://www.scopus.com/inward/record.url?scp=60449088917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60449088917&partnerID=8YFLogxK
U2 - 10.1007/s11606-009-0909-9
DO - 10.1007/s11606-009-0909-9
M3 - Comment/debate
C2 - 19184242
AN - SCOPUS:60449088917
SN - 0884-8734
VL - 24
SP - 421
EP - 426
JO - Journal of general internal medicine
JF - Journal of general internal medicine
IS - 3
ER -